

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	09/645,435
---------------------------	------------

Filing Date	August 24, 2000
--------------------	-----------------

First Named Inventor	FU, C. A.
----------------------	-----------

Group Art Unit	1633
----------------	------

Examiner Name

Attorney Docket Number	A-68344-2 RMS/DHR
------------------------	-------------------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>Carroll</i>	Date Considered	3-15-02
-----------------------	----------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

A circular black ink stamp. The outer ring contains the text "O I P E J C C 3 2" at the top and "P R E N T & T R A D E M A R K O F F I C E" at the bottom. In the center, the date "JAN 23 2002" is stamped. Below the date, the text "P R E N T & T R A D E M A R K O F F I C E" is partially visible.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.


Complete if Known

Application Number	09/645,456
Filing Date	August 24, 2000
First Named Inventor	FU, C. Alan
Group Art Unit	1633
Examiner Name	
Attorney Docket Number	A-68344-3/RMS/DHR

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

RECEIVED
JAN 28 2002
TECH CENTER - 600/2900

Examiner Signature		Date Considered	3-15-02
-----------------------	---	--------------------	---------

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

8086 1449B.FRM (1/01)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

PTO-1449

 ATTY. DOCKET NO.
A-68344-3/RMS/DHR

 SERIAL NO.
09/645,456

 APPLICANT
FU, Alan C.

 FILING DATE
August 24, 2000

 GROUP
1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

- | | |
|----|--|
| 7 | Pombo et al., "Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase", <i>Nature</i> , 377:750:754 (1995). |
| 8 | Shi et al., "Activation of Stress-activated Protein Kinase/c-Jun N-terminal Kinase, but not NF- κ B, by the Tumor Necrosis Factor (TNF) Receptor 1 through a TNF Receptor-associated Factor 2- and Germinal Center Kinase Related-dependent Pathway", <i>J. Biol. Chem.</i> , 272:32102-32107 (1997). |
| 9 | Kiefer et al., "HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway", <i>EMBO J.</i> , 15:7013-7025 (1996). |
| 10 | Diener et al., "Activation of the c-Jun N-terminal kinase pathway by a novel protein kinase related to human germinal center kinase", <i>Proc. Natl. Acad. Sci. USA</i> , 94:9687-9692 (1997). |
| 11 | Yao et al., "A Novel Human STE20-related Protein Kinase, HGK, That Specifically Activates the c-Jun N-terminal Kinase Signaling Pathway", <i>J. Biol. Chem.</i> , 274:2118-2125 (1999). |
| 12 | Su et al., "NIK is a new Ste20-related kinase that binds NCK and MEKK1 and activates the SAPK/JNK cascade via a conserved regulatory domain", <i>EMBO J.</i> , 16:1279-1290 (1997). |
| 13 | Yuasa et al., "Tumor Necrosis Factor Signaling to Stress-activated Protein Kinase (SAPK)/Jun NH ₂ -terminal Kinase (JNK) and p38", <i>J. Biol. Chem.</i> , 273:22681-22692 (1998). |
| 14 | Eichinger et al., "Characterization and Cloning of a <i>Dictyostelium</i> Ste20-like Protein Kinase That Phosphorylates the Actin-binding Protein Severin", <i>J. Biol. Chem.</i> , 273:12952-12959 (1998). |

RECEIVED

MAY 21 2001

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

3-15-02